Trial · NCT06082037
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
NCT06082037, Phase 3, Recruiting, Sanofi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction. Trials, record NCT06082037. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06082037
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
- NCT number
- NCT06082037
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 180 participants, estimated
- Lead sponsor
- Sanofi
- Conditions
- Lung Transplant Rejection
- Interventions
- Belumosudil, Azithromycin, Placebo
- First posted
- 2023-10-13
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent change from baseline to Week 26 in forced expiratory volume in 1 second (FEV1) | Baseline to Week 26 | |
| Secondary | Response rate at Week 26 | Baseline to Week 26 | Defined as the proportion of participants with ≤10% decline in FEV1 at Week 26 compared with baseline |
| Secondary | Absolute change from baseline to Week 26 in FEV1 | Baseline to Week 26 | |
| Secondary | Absolute change from baseline to Week 26 in percent predicted FEV1 | Baseline to Week 26 | |
| Secondary | Percent change from baseline to Week 26 in forced vital capacity (FVC) | Baseline to Week 26 | |
| Secondary | Absolute change from baseline to Week 26 in FVC | Baseline to Week 26 | |
| Secondary | Absolute change from baseline to Week 26 in percent predicted FVC | Baseline to Week 26 | |
| Secondary | Time to CLAD progression during the double-blind treatment period | Baseline to Week 26 | Defined as the first of the following events: \>10% decline in FEV1 compared with baseline, or change in CLAD stage, or re-transplantation, or death |
| Secondary | Time to re-transplantation or death | Up to 7 days after the administration of last dose of study drug | |
| Secondary | Percent change from baseline to Week 26 in 6-minute walk distance | Baseline to Week 26 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06082037
GET https://conductscience.org/api/trials/v1/NCT06082037/registered